These four indications were selected because (i) tumor specimens showed high levels of expression of H19 in the majority of tissues tested from each type of tumor; (ii) animal models supported efficacy in each of these tumors and (iii) each of these malignancies is accessible for loco-regional administration of BC-819. This evidence concerns the gene H19 and neoplasm.